VIDEO: Updated KarMMa-3 results demonstrate safety of idecabtagene vicleucel
Click Here to Manage Email Alerts
Healio spoke with Chakra Chaulagain, MD, about updated safety results from the KarMMa-3 trial presented at ASH 2023.
The trial compared the use of the BCMA-directed CAR-T cell therapy idecabtagene vicleucel (Abecma; Bristol Myers Squibb, 2seventy bio), also known as ide-cel, with standard regimens in patients with triple-class exposed relapsed or refractory multiple myeloma.
The researchers reported that the most severe cytopenias occurred early with ide-cel treatment, that there was a low incidence of prolonged cytopenias and that they were largely manageable. They also reported bacterial infections decreased over time, and viral infections remained the same compared to standard therapy.
Chaulagain, director of the myeloma and amyloidosis program at Cleveland Clinic Florida, noted that ide-cel was also associated with higher increased response rate, minimal residue of disease negativity rate, and extended PFS in these patients.
“If your patient has already received three lines of therapy, it’s time for us to refer that patient to CAR-T cell therapy, and not to continue another cocktail of chemo-immunotherapy,” Chaulagain told Healio.
References
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts